EVT Innovate

EVT Innovate: Building bridges between cutting edge science and transformative pharma projects

Within the EVT Innovate segment, Evotec leverages its proprietary technology platforms to develop new drug discovery projects, assets and platforms, both internally or through collaborations to create starting points for strategic partnerships with Pharma and leading biotech companies in return for upfront payments, ongoing research payments, and significant financial upside through milestones and royalties. Evotec does not take clinical development risks on its own but only within alliances. 
Additionally, Evotec builds translational (BRIDGE) partnerships with Academia and selectively participates in high-potential ventures through strategic investments and company formations through EVT Innovate.

"The development of highly differentiated products requires early translation of breakthrough science. Evotec`s EVT Innovate model is a highly efficient way of translating ground breaking science into product opportunities not only in terms of timelines but also costs." Cord Dohrmann, CSO of Evotec

EVT Innovate at a glance

  • > 150 co-owned potential product opportunities (including EVT equity investments)

  • Primarily first-in-class approaches

  • Leading iPSC platform

  • ~20 academic institutions are Evotec`s strategic partners

  • Over 15 partnered internal programmes since 2011

  • Broad spectrum of disease areas – Diabetes and diabetic complications, inflammatory and immunology, oncology, immuno-oncology, anti-infectives, neuroscience and pain

  • Two spin-offs – Topas Therapeutics and Breakpoint Therapeutics

  • Several holdings in promising start-up biotech companies

  • BRIDGE - a new project incubation paradigm to accelerate research and early development

Contact us


Business Development

T +44.(0)1235.86 15 61 F +44.(0)1235.86 31 39 Get in touch with our experts vCard